Targeting Protein Kinases Degradation by PROTACs
Open Access
- 30 June 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Chemistry
Abstract
Kinase dysregulation is greatly associated with cell proliferation, migration and survival, indicating the importance of kinases as therapeutic targets for anticancer drug development. However, traditional kinase inhibitors binding to catalytic or allosteric sites are associated with significant challenges. The emergence of resistance and targeting difficult-to-degrade and multi-domain proteins are significant limiting factors affecting the efficacy of targeted anticancer drugs. The next-generation treatment approaches seem to have overcome these concerns, and the use of proteolysis targeting chimera (PROTAC) technology is one such method. PROTACs bind to proteins of interest and recruit E3 ligase for degrading the whole target protein via the ubiquitin-proteasome pathway. This review provides a detailed summary of the most recent signs of progress in PROTACs targeting different kinases, primarily focusing on new chemical entities in medicinal chemistry.Keywords
Funding Information
- National Natural Science Foundation of China
- Yunnan Provincial Science and Technology Department
This publication has 134 references indexed in Scilit:
- Reversible targeting of noncatalytic cysteines with chemically tuned electrophilesNature Chemical Biology, 2012
- Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1Cell Death & Disease, 2011
- The histone variant macroH2A suppresses melanoma progression through regulation of CDK8Nature, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- Targeting the phosphoinositide 3-kinase pathway in cancerNature Reviews Drug Discovery, 2009
- CDK8 is a colorectal cancer oncogene that regulates β-catenin activityNature, 2008
- CDK inhibitors in cancer therapy: what is next?Trends in Pharmacological Sciences, 2008
- AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABLBritish Journal of Cancer, 2006
- Focal adhesion kinase: in command and control of cell motilityNature Reviews Molecular Cell Biology, 2005
- Dissemination and growth of cancer cells in metastatic sitesNature Reviews Cancer, 2002